Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif Vyriad and Sanford Health begin Phase I viro-immunotherapy trial http://www.drugdevelopment-technology.com/news/newsvyriad-and-sanford-health-begin-phase-i-viro-immunotherapy-trial-5901459 http://www.drugdevelopment-technology.com/news/newsvyriad-and-sanford-health-begin-phase-i-viro-immunotherapy-trial-5901459 US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours. Tue, 15 Aug 2017 23:00:00 GMT BMS Phase III’s combination trial for RCC meets one co-primary endpoint http://www.drugdevelopment-technology.com/news/newsbms-phase-iiis-combination-trial-for-rcc-meets-one-co-primary-endpoint-5901448 http://www.drugdevelopment-technology.com/news/newsbms-phase-iiis-combination-trial-for-rcc-meets-one-co-primary-endpoint-5901448 Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). Tue, 15 Aug 2017 23:00:00 GMT Researchers demonstrate use of breast cancer drug to shrink brain tumours http://www.drugdevelopment-technology.com/news/newsresearchers-demonstrate-use-of-breast-cancer-drug-to-shrink-brain-tumours-5900790 http://www.drugdevelopment-technology.com/news/newsresearchers-demonstrate-use-of-breast-cancer-drug-to-shrink-brain-tumours-5900790 Researchers from the University of Queensland’s Institute for Molecular Bioscience in Australia and the Fred Hutchinson Cancer Research Centre in the US have conducted a clinical trial to evaluate a previously approved breast cancer drug palbociclib … Tue, 15 Aug 2017 23:00:00 GMT Softigel by Procaps Brochure http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/softigel-corporate-presentation/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/softigel-corporate-presentation/ Procaps is one of the world's largest softgel companies, specialising in the production and development of advanced gelatin-related technologies. Tue, 15 Aug 2017 15:11:00 GMT The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days http://www.drugdevelopment-technology.com/downloads/whitepapers/antibodies/1311/ http://www.drugdevelopment-technology.com/downloads/whitepapers/antibodies/1311/ The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days Tue, 15 Aug 2017 15:11:00 GMT Processability Assessment of Crystal Habit-Modified Active Pharmaceutical Ingredients http://www.drugdevelopment-technology.com/downloads/whitepapers/lab_equipment/processability-assessment-api/ http://www.drugdevelopment-technology.com/downloads/whitepapers/lab_equipment/processability-assessment-api/ The efficiency of downstream processing of active pharmaceutical ingredients (API) can depend on their particulate properties, including size and shape. Tue, 15 Aug 2017 15:10:00 GMT Orthotopic and metastasis models for preclinical efficacy testing of novel cancer drugs http://www.drugdevelopment-technology.com/downloads/whitepapers/contract_research/preclinical-efficacy-testing-novel-cancer-drugs/ http://www.drugdevelopment-technology.com/downloads/whitepapers/contract_research/preclinical-efficacy-testing-novel-cancer-drugs/ Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer. Tue, 15 Aug 2017 15:10:00 GMT PCI Biotech starts dosing in Phase I extension study for bile duct cancer http://www.drugdevelopment-technology.com/news/newspci-biotech-starts-dosing-in-phase-i-extension-study-for-bile-duct-cancer-5900219 http://www.drugdevelopment-technology.com/news/newspci-biotech-starts-dosing-in-phase-i-extension-study-for-bile-duct-cancer-5900219 Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer. Mon, 14 Aug 2017 23:00:00 GMT University of Southampton investigates Acerta’s lymphoma drug http://www.drugdevelopment-technology.com/news/newsuniversity-of-southampton-investigates-acertas-lymphoma-drug-5900231 http://www.drugdevelopment-technology.com/news/newsuniversity-of-southampton-investigates-acertas-lymphoma-drug-5900231 Researchers at the University of Southampton, UK, have initiated a clinical trial to evaluate Acerta Pharma’s new product candidate acalabrutinib in combination with existing standard therapy called R-CHOP to treat select patients with diffuse large … Mon, 14 Aug 2017 23:00:00 GMT Cyclodextrin slows NPC progression in new Washington University trial http://www.drugdevelopment-technology.com/news/newscyclodextrin-slows-npc-progression-in-new-washington-university-trial-5899398 http://www.drugdevelopment-technology.com/news/newscyclodextrin-slows-npc-progression-in-new-washington-university-trial-5899398 A new clinical trial conducted by Washington University School of Medicine in St Louis and the National Institutes of Health (NIH) in the US has shown that a drug called cyclodextrin slows progression of Niemann-Pick type C (NPC) disease. Sun, 13 Aug 2017 23:00:00 GMT Chiasma and FDA agree on new Phase III trial design for acromegaly drug http://www.drugdevelopment-technology.com/news/newschiasma-and-fda-agree-on-new-phase-iii-trial-design-for-acromegaly-drug-5899374 http://www.drugdevelopment-technology.com/news/newschiasma-and-fda-agree-on-new-phase-iii-trial-design-for-acromegaly-drug-5899374 The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acrome… Sun, 13 Aug 2017 23:00:00 GMT Viamet reports positive Phase II data for vulvovaginal candidiasis drug http://www.drugdevelopment-technology.com/news/newsviamet-reports-positive-phase-ii-data-for-vulvovaginal-candidiasis-drug-5899444 http://www.drugdevelopment-technology.com/news/newsviamet-reports-positive-phase-ii-data-for-vulvovaginal-candidiasis-drug-5899444 Viamet Pharmaceuticals has reported positive results from a Phase II clinical trial (REVIVE) of VT-1161 to treat recurrent vulvovaginal candidiasis (RVVC) patients. Sun, 13 Aug 2017 23:00:00 GMT Immunicum starts enrolment in US for Phase II oncology trial http://www.drugdevelopment-technology.com/news/newsimmunicum-starts-enrolment-in-us-for-phase-ii-oncology-trial-5898636 http://www.drugdevelopment-technology.com/news/newsimmunicum-starts-enrolment-in-us-for-phase-ii-oncology-trial-5898636 Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma. Thu, 10 Aug 2017 23:00:00 GMT UK researchers report positive data from new diabetes trial http://www.drugdevelopment-technology.com/news/newsuk-researchers-report-positive-data-from-new-diabetes-trial-5898098 http://www.drugdevelopment-technology.com/news/newsuk-researchers-report-positive-data-from-new-diabetes-trial-5898098 Researchers from King’s College London and Cardiff University in the UK have reported positive results from the new MonoPepT1De clinical trial using immunotherapy for type 1 diabetes. Thu, 10 Aug 2017 23:00:00 GMT Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics http://www.drugdevelopment-technology.com/news/newsdeals-this-week-hitgen-calithera-biosciences-esperion-therapeutics-5896883 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-hitgen-calithera-biosciences-esperion-therapeutics-5896883 HitGen has signed an agreement with LEO Pharma to use its advanced technology platform to discover new small molecules. Thu, 10 Aug 2017 23:00:00 GMT M&As this week: SELLAS Life Sciences Group, Cempra http://www.drugdevelopment-technology.com/news/newsmas-this-week-sellas-life-sciences-group-cempra-5898187 http://www.drugdevelopment-technology.com/news/newsmas-this-week-sellas-life-sciences-group-cempra-5898187 SELLAS Life Sciences Group has signed a definitive agreement to merge with Galena Biopharma. Thu, 10 Aug 2017 23:00:00 GMT Biotecnol and Cancer Research UK to assess Tb535H for solid tumours http://www.drugdevelopment-technology.com/news/newsbiotecnol-and-cancer-research-uk-to-assess-tb535h-for-solid-tumours-5898103 http://www.drugdevelopment-technology.com/news/newsbiotecnol-and-cancer-research-uk-to-assess-tb535h-for-solid-tumours-5898103 Immune-oncology firm Biotecnol and Cancer Research UK have entered a collaboration agreement to evaluate Tb535H in clinical trials to treat patients suffering from solid tumours. Thu, 10 Aug 2017 23:00:00 GMT Allegro’s Phase IIb stage 2 trial for DME drug meets primary endpoint http://www.drugdevelopment-technology.com/news/newsallegros-phase-iib-stage-2-trial-for-dme-drug-meets-primary-endpoint-5897336 http://www.drugdevelopment-technology.com/news/newsallegros-phase-iib-stage-2-trial-for-dme-drug-meets-primary-endpoint-5897336 Biotechnology firm Allegro Ophthalmics has reported positive top-line results from the DEL MAR Phase IIb stage 2 clinical trial of luminate as a sequential therapy to treat diabetic macular edema (DME) patients. Wed, 09 Aug 2017 23:00:00 GMT TapImmune broadens TPIV200’s Phase II trial for ovarian cancer http://www.drugdevelopment-technology.com/news/newstapimmune-broadens-tpiv200s-phase-ii-trial-for-ovarian-cancer-5897327 http://www.drugdevelopment-technology.com/news/newstapimmune-broadens-tpiv200s-phase-ii-trial-for-ovarian-cancer-5897327 US-based immuno-oncology firm TapImmune has amended the Phase II clinical trial of its therapeutic peptide vaccine TPIV200 following discussions with the US Food and Drug Administration (FDA). Wed, 09 Aug 2017 23:00:00 GMT WIN Consortium to conduct targeted tri-therapy trial for NSCLC http://www.drugdevelopment-technology.com/news/newswin-consortium-to-conduct-targeted-tri-therapy-trial-for-nsclc-5897371 http://www.drugdevelopment-technology.com/news/newswin-consortium-to-conduct-targeted-tri-therapy-trial-for-nsclc-5897371 French non-profit healthcare network WIN Consortium (WIN) is set to conduct a clinical trial (SPRING) of a new three targeted therapies combination as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC), following appro… Wed, 09 Aug 2017 23:00:00 GMT